Pallas Health Sermorelin Reviews: Introductory Price, Renewal, and Eligibility

The first payment is not the recurring price

The Pallas sermorelin page advertises $139 for the first month, followed by $597 every 12 weeks. It also describes other plans. Those are separate purchasing arrangements, so confirm the option actually selected before using any figure in a budget.

Pallas labels the recurring offer as a $199 monthly average. Keep the stated 12-week billing interval beside that label. Twelve weeks is 84 days, while three calendar months vary in length. Dividing a charge into three smaller numbers does not establish three separate monthly payments or a calendar-quarter renewal.

Our 12-week billing guide explains how to record the dates. The most useful comparison includes the next charge amount and date, not just a monthly-looking number printed near the purchase button.

Check the age policy before spending time on enrollment

The product FAQ says this program is available to adults age 55 and under under its clinical partner's criteria. Readers over 55 should clarify access before investing time in an intake or assuming a general anti-aging description includes them.

That is a published program policy, not a universal medical cutoff for every form of care. It also does not mean that everyone below the limit is eligible. Pallas describes a clinician's assessment and other medical exclusions; the clinician must determine whether treatment is appropriate.

If the program cannot assess you, ask what kind of evaluation would address your concern. Do not change your age or health information to pass a form. A service's enrollment boundary and the medical explanation for your symptoms are separate questions.

What Pallas says the plan includes

The page describes provider care, medication when prescribed, care-team messaging, check-ins, and shipping within the plan price. Treat that as the provider's service description. Ask whether any testing, additional visits, or other required services would be billed separately in your situation.

Request an itemized confirmation even when the advertising uses one inclusive figure. A useful estimate specifies the selected plan, the period covered, the point at which charging begins, and any charge that falls outside the main subscription.

Compare those categories with the CoreAge Rx review. A lower starting figure or a broader bundle does not by itself demonstrate a better clinical service, and we have not measured patient outcomes for either provider.

Approval and cancellation are different milestones

The Pallas terms distinguish current purchases from earlier arrangements. For purchases on or after September 8, 2026, they describe saving a payment method at checkout and charging when a clinician prescribes. Confirm how that process applies to the chosen sermorelin plan.

The refund policy also distinguishes cancellation before a prescription from cancellation afterward. Its current language says that once the prescription is issued, cancellation stops future charges while the current cycle is generally not prorated or refunded. Read the complete applicable conditions before relying on a short “cancel anytime” label.

Ask for the exact deadline to prevent the next renewal and how the service confirms a cancellation request. Stopping future payments is not the same as reversing work already performed or cancelling medication already prepared.

Do not borrow a guarantee from another treatment

Pallas's general satisfaction language includes weight-related conditions. We would not assume that every part of that policy applies identically to sermorelin or that a commercial refund promise predicts a medical benefit.

If a guarantee affects your decision, ask for written confirmation of its applicability to the exact plan. Identify the required records, exclusions, claim deadline, and eligible payments. Our introductory-price guide helps keep promotional conditions beside the price rather than separated in your notes.

A reader should be able to understand the ordinary recurring offer without relying on a possible future refund. That makes the comparison more practical if the treatment is declined, changed, or discontinued.

Medical claims need a separate review

Pallas cites historical research on GHRH and a related analog. Those references are not a clinical trial of the current Pallas compounded prescription. Ask the clinician which evidence relates to the intended goal, the actual preparation, and your circumstances.

The FDA explains that compounded drugs are not FDA-approved. A prescription process, published references, and transparent pricing do not change that status. This article does not audit a pharmacy or provide an individual treatment recommendation.

Our assessment

Pallas provides a concrete introductory offer and a clearly stated renewal interval, but eligibility needs attention first, particularly for this publication's older readers. The next step is a confirmed care arrangement and a dated explanation of charges if an assessment is appropriate.

Read CoreAge Rx versus Pallas alongside the Promise availability review. Promise's current pause is a reminder that an indexed price may survive after access changes. Compare the offer that exists now, with its conditions intact.